Abstract
Background Controlling novel coronavirus pandemic infection (COVID-19) is a global challenge, and highly sensitive testing is essential for effective control. The saliva is a promising sample for high-sensitivity testing because it is easier to collect than nasopharyngeal swab samples and allows large-volume testing.
Results We developed a simple SARS-CoV-2 concentration method from saliva samples that can be completed in less than 60 min. We performed a spike test using 12 ml of saliva samples obtained from healthy volunteer people, and the developed method performance was evaluated by comparison using a combination of automatic nucleic acid extraction followed by RT-qPCR detection. In saliva spike tests using a 10-fold dilution series of SARS-CoV-2, the developed method was consistently 100-fold more sensitive than the conventional method.
Conclusions The developed method can improve the sensitivity of the SARS-CoV-2 test using saliva and speed up and save labor in screening tests by pooling many samples. Furthermore, the developed method has the potential to contribute to the highly sensitive detection of various human and animal viral pathogens from the saliva and various clinical samples.
Highlight
A method has been developed to detect SARS-CoV-2 from human saliva with 100 times higher sensitivity than conventional methods.
The developed method combines simple pretreatment within 60 min with conventional nucleic acid extraction and RT-qPCR.
This method can be applied for more sensitive virus testing from individual saliva.
This method can potentially be applied to screening more than 100 saliva samples while maintaining the equivalent detection power of conventional methods.
The method can be adapted to improve the sensitivity of detecting various pathogens from human and animal saliva.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by AMED Number JP20he0622031, JSPS KAKENHI Numbers JP21H03180, JP22K05950, JP22KK0097, JSPS Bilateral Program Number JPJSBP120199944, and the Joint Usage/Research Center for Global Collaborative Research, Center for Southeast Asian Studies, Kyoto University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of Kyoto University Graduate School and the Faculty of Medicine approved this study (R2379)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
